Skip to main content

LHRH analog, Abiraterone, and Prednisone in Treating Patients with Stage IV Castration Sensitive Prostate Cancer

Trial Status: Closed to Accrual

This phase Ib trial studies how well LHRH analog, abiraterone, and prednisone work in treating patients with stage IV castration sensitive prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as LHRH analog and abiraterone, may lessen the amount of androgen made by the body. Anti-inflammatory drugs, such as prednisone lower the body’s immune response and are used with other drugs in the treatment of some types of cancer. Giving LHRH analog, abiraterone, and prednisone may help treat patients with prostate cancer.

Inclusion Criteria

  • Histologically or cytologically confirmed adenocarcinoma of the prostate
  • > 75% PSA decline after 12 to 16 weeks of run in period with LHRH, and AR directed therapy
  • Performance status Eastern Cooperative Oncology Group (ECOG) 0-1
  • Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) must be < 2.5 x upper limit of normal (ULN)
  • Total bilirubin < 1.5 X ULN
  • Estimated creatinine clearance must be > 40 mL/min
  • Absolute neutrophil count (ANC) > 1500/l
  • Hemoglobin above 9 g/dl
  • Platelet count > 100,000/l
  • Stable medical condition, including the absence of acute exacerbations of chronic illnesses, serious infections or major surgery within 28 days prior to study enrollment
  • Ability to give written informed consent

Exclusion Criteria

  • Prior LHRH analog with LHRH analogue for non-metastatic prostate cancer within 12 months prior to study enrollment; or > 3 months of LHRH analog in the metastatic setting
  • Prior treatments with TAK-700/Orteronel, ketoconazole, abiraterone, darolutamide, apalutamide or enzalutamide for more than 12 weeks
  • Documented central nervous system metastases or liver metastasis
  • Prior surgical castration
  • Requiring opioids for cancer related pain
  • Treatment with any investigational compound within 30 days prior to the first dose of study drugs
  • Diagnosis or treatment for another systemic malignancy within 2 years before the first dose of study drugs, or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
  • Uncontrolled hypertension despite appropriate medical therapy (blood pressure of greater than 160 mmHg systolic and 100 mmHg diastolic during the screening period). Note: Patients may be rescreened after adjustments of antihypertensive medications
  • Unstable symptomatic ischemic heart disease, ongoing arrhythmias of grade > 2 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], version 5.0), New York Association class III or IV heart failure
  • Known human immunodeficiency virus (HIV) infection, active chronic hepatitis B or C not contained with anti-viral therapy, life threatening illness unrelated to cancer, or any serious medical or psychiatric illness that could, in investigator’s opinion, potentially interfere with participation in this study
  • Known gastrointestinal (GI) disease or GI procedure that could interfere with the GI absorption or tolerance of study drugs, including difficulty swallowing tables
  • Subjects with delayed healing of wounds, ulcers, and/or bone fractures
  • Inability to comply with protocol requirements


Moffitt Cancer Center
Contact: Jingsong Zhang
Phone: 813-745-1363


I. Test the feasibility of adaptive luteinizing hormone releasing hormone (LHRH) analog in patients with asymptomatic metastatic castration sensitive prostate cancer (mCSPC).


I. Assess the clinical benefits of adaptive LHRH analog by comparing to historical controls.


I. Detect the intra-tumor heterogeneity of androgen receptor (AR) and Cyp17 immunohistochemistry (IHC) stains on formalin-fixed paraffin-embedded (FFPE) blocks of prostate tumors and or metastatic lesions.

II. Refine the mathematical model for adaptive androgen deprivation therapy (ADT).

III. To develop imaging habitat biomarkers to track diseases progression using the patients’ computed tomography (CT) and bone scans and compare with conventional progression variables (like prostate specific antigen [PSA]).

IV. Compare the AR, Cyp17 immunohistochemistry (IHC) stains as well as imaging biomarkers with a retrospective cohort of mCSPC patients who underwent continuous LHRH analog as standard of care.

V. Detect and track the changes of AR mutations and AR amplification in tumor cell free deoxyribonucleic acid (DNA).


Patients receive standard of care gonadotropin-releasing hormone analog via injections and luteinizing hormone releasing hormone (LHRH) such as leuprolide, goserelin, or triptorelin for 12-16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive gonadotropin-releasing hormone analog, and either abiraterone orally (PO) daily and prednisone PO once daily (QD), enzalutamide PO daily, or apalutamide PO daily for 8-12 weeks in the absence of disease progression of unacceptable toxicity. Patients who develop PSA or radiographic progression per prostate cancer working group (PCWG) criteria while on off treatment surveillance, may restart treatment.

After completion of study treatment, patients are followed up at 4-6 weeks.

Trial Phase Phase I

Trial Type Treatment

Lead Organization
Moffitt Cancer Center

Principal Investigator
Jingsong Zhang

  • Primary ID MCC-19367
  • Secondary IDs NCI-2018-01095
  • ID NCT03511196